With the goal of offering a seamless transition from preclinical testing to clinical work, Theorem Clinical Research and Charles River Laboratories have formed an alliance that will provide nonclinical testing programs in the areas of bioanalysis, immunogenicity, and immunology to support trials.
"Charles River develops and validates assays in support of nonclinical programs, and many of these assays can be validated for human matrix and used for analyzing clinical samples," said Marc Hoffman, M.D., senior vice president and general manager of biopharmaceutical development at Theorem.
In the last three months, Theorem has entered three strategic alliances with other service providers to expand the breadth of its offerings. It will focus on medical product development with Ximedica, imaging with RadMD, and servicing the medical device and in vitro diagnostics community with Emergo Group.
According to Charles River, its high-quality research models, preclinical testing capabilities, and clinical support services are backed by a comprehensive bioanalysis portfolio for non-GLP and GLP programs.
This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.